Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Lung cancer patients can be screened for ALK-inhibitor suitability

Anaplastic lymphoma kinase gene status in patients with lung adenocarcinoma can be determined non-invasively using circulating tumor cells, research shows.

8 Aug 2012

Elderly NSC lung cancer patients benefit from concurrent chemoradiation

Fit older adults with locally advanced non-small-cell lung cancer reap similar benefit from concurrent chemoradiation with etoposide and cisplatin as younger patients, but experience higher rates of hospitalization and toxicity, research shows.

8 Aug 2012

Folate, excision biomarkers not predictive for small-cell lung cancer response

Biomarkers associated with the folate metabolism and excision repair pathways are not sufficiently prognostic to aid chemotherapy decisions for patients with extensive-stage disease small-cell lung cancer, results of a phase III trial show.

8 Aug 2012

Chemotherapy is appropriate adjunct to surgery for oral melanoma in dogs

The addition of chemotherapeutic treatment with carboplatin for dogs with oral malignant melanomas that have undergone surgical excision may be a reasonable alternative to adjunctive radiotherapy, report researchers.

8 Aug 2012

Hospice cancer patients adhere well to pain meds

Study results from the midwest USA indicate that hospice-treated older individuals with cancer are highly adherent to pain medication, but that as they become more comfortable, adherence wanes.

8 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects

Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.

8 Aug 2012

Dental health linked to falls in Japanese elderly

Japanese study results indicate that elderly individuals with 19 or fewer teeth who do not wear dentures are at a greater risk for incident falls than their counterparts with 20 teeth or more.

7 Aug 2012

Surprise result in caffeine trial for Parkinson’s patients

Caffeine treatment may improve motor symptoms in patients with Parkinson’s disease, research suggests.

7 Aug 2012

USPTO issues patent to Aeterna Zentaris’ AEZS-130 oral test for AGHD

Aeterna Zentaris Inc. today announced that the United States Patent and Trademark Office has granted a patent for the use of its oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency.

7 Aug 2012

Applied BioCode receives U.S. patent for ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United Stated Patent and Trademark Office has granted US Patent #8,232,092 "Light Transmitted Assay Beads," describing the method of decoding barcodes and analyzing bioassays using Barcoded Magnetic Beads (BMB) multiplex products.

7 Aug 2012

Clinical trial targets breast cancer cells by injecting trastuzumab directly into the spinal fluid

In two to five percent of women with breast cancer, tumor cells migrate into the spinal fluid invading the tissue surrounding the brain and spinal cord called the meninges. While a rare complication, the condition is challenging because there is no agreed-upon standard of treatment, leaving little hope for patients affected. Northwestern Medicine- researchers are currently examining a novel approach to delivering an FDA approved drug that they hope will advance research for this type of cancer and lead to discoveries that may improve outcomes in the future.

7 Aug 2012

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

7 Aug 2012

Adiposity linked to cognitive decline in elderly

High levels of adiposity increase rates of cognitive decline in the “young elderly” aged between 60 and 70 years, report Korean researchers.

6 Aug 2012

New Translational Oncology Program at University of Michigan

The University of Michigan Comprehensive Cancer Center is harnessing its expertise in basic science research to speed the translation into clinical trials and new treatment opportunities for cancer patients.

6 Aug 2012

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $48.2 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer researchers.

6 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

6 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.

6 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012